A Phase 1 interventional study of Levothyroxine and Enlicitide Decanoate in Healthy, sponsored by Merck Sharp & Dohme LLC. Completed at 1 site in United States. Open to participants aged 19 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-10-03.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Levothyroxine (T4) is a man-made thyroid hormone used to treat certain thyroid conditions. After taking levothyroxine, a person's body changes it to triiodothyronine (T3). The amount of levothyroxine in a person's blood must be carefully controlled to maintain proper function. Enlicitide decanoate was designed to lower the amount of cholesterol in a person's blood.
Researchers want to learn about levothyroxine when taken at the same time with enlicitide decanoate. They want to:
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
The key inclusion criteria include but are not limited to the following:
Exclusion Criteria:
The key exclusion criteria include but are not limited to the following:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive a single oral dose of levothyroxine.
Drug: Levothyroxine
Participants will receive a single oral dose of levothyroxine and a single oral dose of enlicitide decanoate at the same time.
Drug: Levothyroxine · Drug: Enlicitide Decanoate
single oral dose
Also known as: Synthroid
single oral dose
Also known as: MK-0616
Area under the Concentration-Time Curve from Time 0 to 48 hours (AUC0-48hrs) of Levothyroxine (total T4)
Blood samples will be collected to determine the AUC0-48hr of Levothyroxine (T4).
Time frame: At designated timepoints (up to approximately 48 hours postdose)
Maximum Plasma Concentration (Cmax) of Levothyroxine (total T4)
Blood samples will be collected to determine the Cmax of Levothyroxine (T4).
Time frame: At designated timepoints (up to approximately 48 hours postdose)
Time to Maximum Plasma Concentration (Tmax) of Levothyroxine (total T4)
Blood samples will be collected to determine the Tmax of Levothyroxine (T4).
Time frame: At designated timepoints (up to approximately 48 hours postdose)
Area under the Concentration-Time Curve from Time 0 to 48 hours (AUC0-48hrs) of Triiodothyronine (total T3)
Blood samples will be collected to determine the AUC0-48hr of triiodothyronine (T3).
Time frame: At designated timepoints (up to approximately 48 hours postdose)
Maximum Plasma Concentration (Cmax) of Triiodothyronine (total T3)
Blood samples will be collected to determine the Cmax of triiodothyronine (T3).
Time frame: At designated timepoints (up to approximately 48 hours postdose)
Time to Maximum Plasma Concentration (Tmax) of Triiodothyronine (total T3)
Blood samples will be collected to determine the Tmax of triiodothyronine (T3).
Time frame: At designated timepoints (up to approximately 48 hours postdose)
Number of Participants Who Experience a Treatment-Emergent Adverse Event (TEAE)
An adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE will be considered treatment-emergent if the onset date and time is at the time of or after the first study drug administration. The number of participants who experience a TEAE will be reported.
Time frame: Up to approximately 7 weeks
Number of Participants Who Discontinue Study Due to a TEAE
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE will be considered treatment-emergent if the onset date and time is at the time of or after the first study drug administration. The number of participants who discontinue study due to a TEAE will be reported.
Time frame: Up to approximately 7 weeks
Plan to share: Yes — http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf
Data sharing details ↗ · engagezone.msd.com
Ran from Jul 2024 to primary completion in Aug 2024, 1 month.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Thyroxine · MK-0616